Aveanna Healthcare (NASDAQ:AVAH) Major Shareholder Paul Vigano Sells 14,500,002 Shares

Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH) major shareholder Paul Vigano sold 14,500,002 shares of Aveanna Healthcare stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $166,750,023.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Aveanna Healthcare Price Performance

Shares of Aveanna Healthcare stock traded up $0.54 during trading on Monday, hitting $13.70. 5,371,630 shares of the stock traded hands, compared to its average volume of 1,804,159. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 4.47. The stock has a market cap of $2.99 billion, a price-to-earnings ratio of 11.14, a PEG ratio of 0.92 and a beta of 1.90. The firm’s fifty day moving average is $9.58 and its 200-day moving average is $7.92. Aveanna Healthcare Holdings Inc. has a 52 week low of $5.93 and a 52 week high of $13.98.

Aveanna Healthcare (NASDAQ:AVAH) last released its earnings results on Thursday, August 13th. The company reported $0.22 earnings per share for the quarter, topping analysts’ consensus estimates of $0.17 by $0.05. The company had revenue of $670.48 million during the quarter, compared to the consensus estimate of $638.61 million. Aveanna Healthcare had a return on equity of 80.70% and a net margin of 10.56%. Research analysts expect that Aveanna Healthcare Holdings Inc. will post 0.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of AVAH. Vanguard Group Inc. raised its holdings in Aveanna Healthcare by 38.0% in the fourth quarter. Vanguard Group Inc. now owns 5,577,010 shares of the company’s stock worth $45,564,000 after purchasing an additional 1,535,351 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Aveanna Healthcare by 49.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,334,374 shares of the company’s stock valued at $8,593,000 after buying an additional 441,707 shares in the last quarter. Segall Bryant & Hamill LLC grew its position in shares of Aveanna Healthcare by 425.8% in the 1st quarter. Segall Bryant & Hamill LLC now owns 163,966 shares of the company’s stock worth $1,056,000 after buying an additional 132,779 shares during the period. NFJ Investment Group LLC bought a new position in shares of Aveanna Healthcare in the 2nd quarter worth about $2,682,000. Finally, Weiss Asset Management LP bought a new position in shares of Aveanna Healthcare in the 1st quarter worth about $732,000. Hedge funds and other institutional investors own 87.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AVAH. Wall Street Zen lowered shares of Aveanna Healthcare from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 15th. Weiss Ratings restated a “hold (c+)” rating on shares of Aveanna Healthcare in a research report on Thursday, July 2nd. BMO Capital Markets raised their price objective on Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a research note on Friday, August 14th. Barclays lifted their price objective on Aveanna Healthcare from $9.00 to $9.50 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Stephens upgraded Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $10.00 to $11.00 in a report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.89.

Key Stories Impacting Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Royal Bank of Canada raised its price target for Aveanna Healthcare from $10 to $16 and upgraded the stock to “outperform.” The new target implies additional upside from recent trading levels, providing a bullish signal for AVAH. Benzinga analyst price-target report
• Neutral Sentiment: Truist Financial increased its price target from $11 to $15 but maintained a “hold” rating. The higher valuation suggests improved expectations, while the unchanged rating indicates the firm does not see a compelling reason to become more bullish after the stock’s recent advance. Benzinga analyst price-target report
• Negative Sentiment: Several insiders sold a combined 320,000 shares at an average price of $11.50, generating approximately $3.68 million. CEO Jeff Shaner sold 90,000 shares, director Rodney D. Windley sold 180,000, and insider Edwin C. Reisz sold 50,000. Each retained a substantial stake, but the coordinated sales—particularly Windley’s roughly 8% position reduction—could raise concerns about insider confidence or add near-term selling pressure. CEO insider sale filing Director insider sale filing Insider sale filing

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.